文献速递腹部泌尿生殖MRUS

肝硬化患者超声检出≤2 cm结节中LI-RADS 3类的磁共振评估

Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients.
PubMed 文献 · Eur Radiol · 2021-01-06

该研究回顾性纳入262例肝硬化患者超声新检出单发≤20 mm结节,评估LI-RADS v2018联合细胞外对比剂MRI的诊断准确性;LR-3结节中68.9%(51/74)为HCC,LR-5敏感度64%、特异度98.5%,LR-3结节的HCC诊断与基线肿瘤大小密切相关。

要点

  • 超声检出≤20 mm结节中,MRI判为LR-3的病灶68.9%(51/74)最终为HCC。
  • LR-3中≤1 cm的5枚结节均诊断为良性,>15 mm的21枚中20枚(95.2%)为HCC。
  • LR-5诊断HCC敏感度64%、特异度98.5%;联合LR-4后敏感度69.5%、特异度96.2%。

诊断标准与关键数值

  • 最终诊断:197例HCC(75.2%)、5例胆管癌(1.9%)、2例转移瘤(0.8%)、58例良性病变(22.1%)。
  • 各LR类别中HCC比例:LR-1为0/15(0%)、LR-2为6/26(23.1%)、LR-3为51/74(68.9%)、LR-4为11/12(91.7%)、LR-5为126/127(99.2%)、LR-M为3/8(37.5%)。
  • LR-5诊断HCC的敏感度64%(95%CI 56.8-70.7)、特异度98.5%(95%CI 91.7-100)。
  • 将LR-4也视为HCC诊断时,敏感度略升至69.5%(95%CI 62.6-75.9),特异度影响较小,为96.2%(95%CI 89.3-99.6)。
  • LR-3观察对象中51/74为HCC、2例为非HCC恶性肿瘤;LR-3中>15 mm的结节20/21(95.2%)最终归类为HCC。

临床应用与阅片要点

  • 作者认为,超声检出的LR-3观察对象HCC概率高(68.9%),若拟在极早期诊断HCC,可据此启动积极的诊断检查。
  • LR-3结节的HCC诊断与基线肿瘤大小密切相关:≤1 cm的5枚结节均诊断为良性,>15 mm的21枚中20枚(95.2%)为HCC。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: Liver Imaging Reporting and Data System (LI-RADS) for hepatocellular carcinoma (HCC) diagnosis in high-risk patients is a dynamic system, which was lastly updated in 2018. We aimed to evaluate the accuracy for HCC diagnosis of LI-RADS v2018 with magnetic resonance imaging (MRI) with extracellular contrast for solitary nodules ≤ 20 mm detected during ultrasound (US) surveillance in cirrhotic patients, with particular interest in those observations categorized as LI-RADS 3.

METHODS: Between November 2003 and February 2017, we included 262 consecutive cirrhotic patients with a newly US-detected solitary ≤ 20-mm nodule. A LI-RADS (LR) v2018 category was retrospectively assigned. The diagnostic accuracy for each LR category was described, and the main MRI findings associated with HCC diagnosis were analyzed.

RESULTS: Final diagnoses were as follows: 197 HCC (75.2%), 5 cholangiocarcinoma (1.9%), 2 metastasis (0.8%), and 58 benign lesions (22.1%); 0/15 (0%) LR-1, 6/26 (23.1%) LR-2, 51/74 (68.9%) LR-3, 11/12 (91.7%) LR-4, 126/127 (99.2%) LR-5, and 3/8 (37.5%) LR-M were HCC. LR-5 category displayed a sensitivity and specificity of 64% (95% CI, 56.8-70.7) and 98.5% (95% CI, 91.7-100), respectively. Considering also LR-4 as diagnostic for HCC, the sensitivity slightly increased to 69.5% (95% CI, 62.6-75.9) with minor impact on specificity (96.2%; 95% CI, 89.3-99.6). Regarding LR-3 observations, 51 out of 74 were HCC, 2 were non-HCC malignancies, and 20 out of 21 LR-3 nodules > 15 mm (95.2%) were finally categorized as HCC.

CONCLUSIONS: The high probability of HCC in US-detected LR-3 observations (68.9%) justifies triggering an active diagnostic work-up if intended to diagnose HCC at a very early stage.

KEY POINTS: • In cirrhotic patients with nodules ≤ 20 mm detected during US surveillance, 51 out of 74 (68.9%) of LR-3 nodules by MRI corresponded to an HCC. • In LR-3 nodules, HCC diagnosis was closely related to baseline tumor size. All 5 nodules smaller than 1 cm were diagnosed as benign. Oppositely, 20 out of 21 LR-3 observations > 15 mm (95.2%) were diagnosed as HCC. • The high probability of HCC in US-detected LR-3 observations justifies triggering an active diagnostic work-up if intended to diagnose HCC at a very early stage.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Darnell A, Rimola J, Belmonte E, et al. Evaluation of LI-RADS 3 category by magnetic resonance in US-detected nodules ≤ 2 cm in cirrhotic patients. Eur Radiol. 2021. PMID: 33409789. doi:10.1007/s00330-020-07457-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。